The global leader in large-scale biologics and biosimilars. Compare MFDS-regulated Korean CDMOs across biologics and drug product — by capability and site.
South Korea is the world leader in large-scale biologics and biosimilar manufacturing, home to some of the largest single-site bioreactor capacity on the planet. Its CDMO sector is concentrated around the Songdo (Incheon) biocluster and built for commercial-scale antibody and biosimilar production.
Korean facilities are regulated by the MFDS, which participates in PIC/S and international harmonization, and major Korean CDMOs hold FDA and EU GMP approvals for global supply. For commercial-scale biologics, South Korea offers capacity and speed that few markets can match.
South Korea is the natural choice for sponsors who need very large-scale biologics or biosimilar manufacturing capacity with proven global regulatory standing — its mega-facilities are purpose-built for commercial antibody production.
No companies found in this category yet. Check back soon.
Browse all CDMOsHow this list is built: companies appear here when they have a manufacturing site in South Korea in our facilities dataset and pass the marketplace eligibility gate (pharmaceutical contract manufacturers only — CROs, equipment suppliers, and other non-manufacturers are excluded). Read the full methodology for the eligibility gates and how our ranked lists are computed.
Our AI Matchmaker analyzes your project requirements and matches you with qualified South Korea manufacturing partners. Free for buyers.